Boundless Bio Inc宣布通过产品组合优先排序计划,显著延长了公司的运营资金期限。这一战略调整包含终止其名为Potentiate的临床试验项目。经过此番优化,公司预计现有资金将足以支持运营至2028年下半年。
Boundless Bio Inc宣布通过产品组合优先排序计划,显著延长了公司的运营资金期限。这一战略调整包含终止其名为Potentiate的临床试验项目。经过此番优化,公司预计现有资金将足以支持运营至2028年下半年。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.